Publications of Elena Pugacheva

Dual targeting of mesenchymal and amoeboid motility hinders metastatic behavior.
Jones BC, Kelley LC, Loskutov YV, Marinak KM, Kozyreva VK, Smolkin MB, Pugacheva EN.
Mol Cancer Res. 2017.

Combination of Eribulin and Aurora A inhibitor MLN8237 prevents metastatic colonization and induces cytotoxic autophagy in breast cancer.
Kozyreva VK, Kiseleva A, Ice RJ, Jones BC, Loskutov YV, Matalkah F, Smolkin MB, Marinak K, Livengood RH, Salkeni MA, Wen S, Hazard HW, Layne GP, Walsh CM, Cantrell PS, Kilby GW, Mahavadi S, Shah N, Pugacheva EN.
Mol Cancer Ther. 2016; 15(8): 1809-1822.


Direct contact with perivascular tumor cells enhances integrin alphavbeta3 signaling and migration of endothelial cells.
Burgett ME, Lathia JD, Roth P, Nowacki AS, Galileo DS, Pugacheva EN, Huang P, Vasanji A, Li M, Byzova T, Mikkelsen T, Bao S, Rich JN, Weller M, Gladson CL.
Oncotarget. 2016; 7(28): 43852-43867.


AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis.
Park J, Schlederer M, Schreiber M, Kim S, Ice RJ, Merkel O, Bilban M, Hofbauer S, Addison JB, Zou J, Ji CY, Bunting S, Wang Z, Shoham M, Huang G, Bago-Horvath Z, Gibson LF, Rojanasakul Y, Remick SC, Ivanov AV, Pugacheva EN, Bunting KD, Moriggl R, Kenner L, Tse WW.
Oncotarget. 2015; 6(24): 20697-20710.


NEDD9/Arf6-dependent endocytic trafficking of matrix metalloproteinase 14: a novel mechanism for blocking mesenchymal cell invasion and metastasis of breast cancer.
Loskutov YV, Kozyulina PY, Kozyreva VK, Ice RJ, Jones BC, Roston TJ, Smolkin MB, Ivanov AV, Wysolmerski RB, Pugacheva EN.
Oncogene. 2015; 34(28): 3662-3675.


Kruppel-like factor 4 signals through microRNA-206 to promote tumor initiation and cell survival.
Lin CC, Sharma SB, Farrugia MK, McLaughlin SL, Ice RJ, Loskutov YV, Pugacheva EN, Brundage KM, Chen D, Ruppert JM.
Oncogenesis. 2015; 4: e155.


Pro-metastatic NEDD9 regulates individual cell migration via caveolin-1-dependent trafficking of integrins.
Kozyulina PY, Loskutov YV, Kozyreva VK, Rajulapati A, Ice RJ, Jones BC, Pugacheva EN.
Mol Cancer Res. 2015; 13(3): 423-438.


Role for chondroitin sulfate glycosaminoglycan in NEDD9-mediated breast cancer cell growth.
Iida J, Dorchak J, Clancy R, Slavik J, Ellsworth R, Katagiri Y, Pugacheva EN, van Kuppevelt TH, Mural RJ, Cutler ML, Shriver CD.
Exp Cell Res. 2015; 330(2): 358-370.

KAP1 promotes proliferation and metastatic progression of breast cancer cells.
Addison JB, Koontz C, Fugett JH, Creighton CJ, Chen D, Farrugia MK, Padon RR, Voronkova MA, McLaughlin SL, Livengood RH, Lin CC, Ruppert JM, Pugacheva EN, Ivanov AV.
Cancer Res. 2015; 75(2): 344-355.


NEDD9 depletion leads to MMP14 inactivation by TIMP2 and prevents invasion and metastasis.
McLaughlin SL, Ice RJ, Rajulapati A, Kozyulina PY, Livengood RH, Kozyreva VK, Loskutov YV, Culp M, Weed SA, Ivanov AV, Pugacheva EN.
Mol Cancer Res. 2014; 12(1): 69-81.


NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner.
Kozyreva VK, McLaughlin SL, Livengood RH, Calkins RA, Kelley LC, Rajulapati A, Ice RJ, Smolkin MB, Weed SA, Pugacheva EN.
Mol Cancer Res. 2014; 12(5): 681-693.


NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumors.
Ice RJ, McLaughlin SL, Livengood RH, Culp M, Eddy ER, Ivanov AV, Pugacheva EN.
Cancer Res. 2013; 73(10): 3168-3180.


NEDD9 stabilizes focal adhesions, increases binding to the extra-cellular matrix and differentially effects 2D versus 3D cell migration.
Zhong J, Baquiran JB, Bonakdar N, Lees J, Ching YW, Pugacheva EN, Fabry B, O'Neill GM.
PLoS One. 2012; 7(4): e35058.


Calmodulin activation of Aurora-A (AURKA) is required during ciliary disassembly and in mitosis.
Plotnikova OV, Nikonova AS, Loskutov YV, Kozyulina PY, Pugacheva EN, Golemis EA.
Mol Cell Biol. 2012; 23(14): 2658-2670.


Abl family kinases modulate T cell-mediated inflammation and chemokine-induced migration through the adaptor HEF1 and the GTPase Rap1.
Gu JJ, Lavau CP, Pugacheva EN, Soderblom EJ, Moseley MA, Pendergast AM.
Sci Signal. 2012; 5(233): ra51.


Aurora A kinase activity influences calcium signaling in kidney cells.
Plotnikova OV, Pugacheva EN, Golemis EA.
J Cell Biol. 2011; 193(6): 1021-1032.


Rapid calcium-dependent activation of Aurora-A kinase.
Plotnikova OV, Pugacheva EN, Dunbrack RL, Golemis EA.
Nat Commun. 2010; 1: 64.


The WW-HECT protein Smurf2 interacts with the docking protein NEDD9/HEF1 for Aurora A activation.
Moore FE, Osmundson EC, Koblinski J, Pugacheva EN, Golemis EA, Ray D, Kiyokawa H.
Cell Div. 2010; 5: 22.


NEDD9 promotes oncogenic signaling in mammary tumor development.
Izumchenko E, Singh MK, Plotnikova OV, Tikhmyanova N, Little JL, Serebriiskii IG, Seo S, Kurokawa M, Egleston BL, Klein-Szanto AJP, Pugacheva EN, Hardy RR, Wolfson M, Connolly DC, Golemis EA.
Cancer Res. 2009; 69(18): 7198-7206.


Cell cycle-dependent ciliogenesis and cancer.
Plotnikova OV, Golemis EA, Pugacheva EN.
Cancer Res. 2008; 68(7): 2058-2061.


HEF1-dependent Aurora A activation induces disassembly of the primary cilium.
Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA.
Cell. 2007; 129(7): 1351-1363.


Interdependence of cell attachment and cell cycle signaling.
Pugacheva EN, Roegiers F, Golemis EA.
Curr Opin Cell Biol. 2006; 18(5): 507-515.


HEF1-aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks.
Pugacheva EN, Golemis EA.
Cell Cycle. 2006; 5(4): 384-391.


HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells.
Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD, Wang W, Grammer JR, Gladson CL.
Oncogene. 2006; 25(12): 1721-1732.

Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA activation cycle.
Dadke D, Jarnik M, Pugacheva EN, Singh MK, Golemis EA.
Mol Cell Biol. 2006; 17(3): 1204-1217.


The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome.
Pugacheva EN, Golemis EA.
Nat Cell Biol. 2005; 7(10): 937-946.


Detection of peptides, proteins, and drugs that selectively interact with protein targets.
Serebriiskii IG, Mitina O, Pugacheva EN, Benevolenskaya E, Kotova E, Toby GG, Khazak V, Kaelin WG, Chernoff J, Golemis EA.
Genome Res. 2002; 12(11): 1785-1791.


Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil.
Pugacheva EN, Ivanov AV, Kravchenko JE, Kopnin BP, Levine AJ, Chumakov PM.
Oncogene. 2002; 21(30): 4595-4600.

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva EN, Chumakov PM, Bergman J, Wiman KG, Selivanova G.
Nat Med. 2002; 8(3): 282-288.

Signal transduction driving technology driving signal transduction: factors in the design of targeted therapies.
Golemis EA, Ochs MF, Pugacheva EN.
J Cell Biochem Suppl. 2001; Suppl 37: 42-52.

[Identification of genes activated by mutant forms of p53].
Pugacheva EN, Ivanov AV, Snegur IE, Kopnin BP, Chumakov PM.
Mol Biol (Mosk). 2000; 34(1): 143-151.

[The human adenosine deaminase gene contains a p53-responsive element].
Kondratov RV, Pugacheva EN, Kuznetsov NV, Prasolov VS, Kopnin BP, Chumakov PM.
Dokl Akad Nauk. 1996; 346(2): 260-262.

[Functional heterogeneity of p53-responsive elements].
Kondratov RV, Kuznetsov NV, Pugacheva EN, Almazov VP, Prasolov VS, Kopnin BP, Chumakov PM.
Mol Biol (Mosk). 1996; 30(3): 613-620.

Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts.
Kopnin BP, Stromskaya TP, Kondratov RV, Ossovskaya VS, Pugacheva EN, Rybalkina EY, Khokhlova OA, Chumakov PM.
Oncol Res. 1995; 7(6): 299-306.

[p53 with a mutation in codon 273 increases the probability of amplifying the dhfr gene in Rat-1 and LIM1215 cells].
Il'inskaia GV, Pugacheva EN, Sokova OI, Chumakov PM, Kopnin BP.
Genetika. 1995; 31(5): 611-616.